Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study.
PCSK9
alirocumab
endothelial function
lipids
magnetic resonance
ultrasound
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
11 Jan 2022
11 Jan 2022
Historique:
received:
30
11
2021
revised:
04
01
2022
accepted:
06
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Short-term effects of alirocumab on vascular function have hardly been investigated. Moreover, there is a scarce of reliable non-invasive methods to evaluate atherosclerotic changes of the vasculature. The ALIROCKS trial was performed to address these issues using standard ultrasound-based procedures and a completely novel magnetic resonance-based imaging technique. A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were 2 visits to the study site, the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. The key outcome measures included the change of carotid vessel wall fractional anisotropy, a novel magnetic resonance-based measure of vascular integrity, and the changes of carotid intima-media thickness and flow-dependent dilatation of the brachial artery measured with ultrasound. A total of 19 patients completed the trial, 2 patients stopped treatment, 3 patients did not undergo the second visit due to the COVID pandemic. All of them had atherosclerotic vascular disease. Their mean (standard deviation) LDL-cholesterol concentration was 154 (85) mg/dL at baseline and was reduced by 76 (44) mg/dL in response to alirocumab treatment ( Despite a nominal amelioration for flow-dependent dilatation, significant effects of short-term treatment with alirocumab on vascular function were not detectable. More work would be needed to evaluate, whether fractional anisotropy may be useful in clinical atherosclerosis research.
Sections du résumé
BACKGROUND
BACKGROUND
Short-term effects of alirocumab on vascular function have hardly been investigated. Moreover, there is a scarce of reliable non-invasive methods to evaluate atherosclerotic changes of the vasculature. The ALIROCKS trial was performed to address these issues using standard ultrasound-based procedures and a completely novel magnetic resonance-based imaging technique.
METHODS
METHODS
A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were 2 visits to the study site, the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. The key outcome measures included the change of carotid vessel wall fractional anisotropy, a novel magnetic resonance-based measure of vascular integrity, and the changes of carotid intima-media thickness and flow-dependent dilatation of the brachial artery measured with ultrasound.
RESULTS
RESULTS
A total of 19 patients completed the trial, 2 patients stopped treatment, 3 patients did not undergo the second visit due to the COVID pandemic. All of them had atherosclerotic vascular disease. Their mean (standard deviation) LDL-cholesterol concentration was 154 (85) mg/dL at baseline and was reduced by 76 (44) mg/dL in response to alirocumab treatment (
CONCLUSION
CONCLUSIONS
Despite a nominal amelioration for flow-dependent dilatation, significant effects of short-term treatment with alirocumab on vascular function were not detectable. More work would be needed to evaluate, whether fractional anisotropy may be useful in clinical atherosclerosis research.
Identifiants
pubmed: 35052831
pii: biomedicines10010152
doi: 10.3390/biomedicines10010152
pmc: PMC8773704
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):282-291
pubmed: 31653513
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):237-245
pubmed: 31236571
J Am Soc Echocardiogr. 2020 Aug;33(8):917-933
pubmed: 32600741
J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021
pubmed: 30336824
Circ J. 2010 Jan;74(1):195-202
pubmed: 19926918
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Vasa. 2015 Nov;44(6):444-50
pubmed: 26515221
J Am Coll Cardiol. 2015 Aug 4;66(5):495-507
pubmed: 26227186
Can J Physiol Pharmacol. 2019 May;97(5):352-358
pubmed: 30875237
Circulation. 2005 May 10;111(18):2356-63
pubmed: 15867181
Circ J. 2019 Sep 25;83(10):2025-2033
pubmed: 31434809
PLoS One. 2014 Apr 16;9(4):e93357
pubmed: 24740106
Thromb Res. 2020 Oct;194:229-236
pubmed: 33213848
Eur Heart J. 2018 Sep 14;39(35):3337
pubmed: 29584867
Chin Med J (Engl). 2016 Jan 20;129(2):215-26
pubmed: 26830994
Atherosclerosis. 2001 Aug;157(2):369-73
pubmed: 11472736
J Cardiovasc Magn Reson. 2016 Nov 23;18(1):81
pubmed: 27876066
J Clin Med. 2020 Jul 16;9(7):
pubmed: 32708615
Curr Med Res Opin. 2020 Sep;36(9):1419-1425
pubmed: 32568565
N Engl J Med. 2018 Nov 29;379(22):2097-2107
pubmed: 30403574
JAMA. 2016 Dec 13;316(22):2373-2384
pubmed: 27846344
Atherosclerosis. 2015 Aug;241(2):507-32
pubmed: 26117398
J Cardiol. 2020 Mar;75(3):289-295
pubmed: 31495548
Atherosclerosis. 2011 Dec;219(2):596-602
pubmed: 21868017
Eur Radiol. 2010 Oct;20(10):2533-40
pubmed: 20432038
Eur Heart J. 2015 Feb 21;36(8):490-500
pubmed: 25182248
JACC Cardiovasc Imaging. 2019 Dec;12(12):2571-2573
pubmed: 31422119
Cardiovasc Ther. 2008 Winter;26(4):253-61
pubmed: 19035876
Int J Cardiol. 2005 May 11;101(1):65-70
pubmed: 15860385
J Cardiovasc Pharmacol. 2019 Sep;74(3):266-269
pubmed: 31356537
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Clin Lipidol. 2018 May - Jun;12(3):669-673
pubmed: 29544724
JACC Cardiovasc Imaging. 2020 Jun;13(6):1452-1454
pubmed: 32199850
Cardiovasc Diagn Ther. 2021 Feb;11(1):120-129
pubmed: 33708484